AstraZeneca Plc (AZN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH3904D
- Pages: 601
- October 2018
- Total Views:1149
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. It is also developing new approaches to the treatment of asthma. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
AstraZeneca Plc (AZN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 13
List of Figures 19
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deal Details 48
Asset Purchase 48
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53
MedImmune Acquires Patent Rights and Technologies from Allozyne 55
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60
AstraZeneca Acquires Neuroscience Assets From Link Medicine 62
Venture Financing 63
PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63
Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65
Albireo to Raise USD10 Million in Venture Financing 67
G1 Therapeutics Raises USD47 Million in Series C Financing 68
Rani Therapeutics Raises Funds in Financing 70
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72
G1 Therapeutics Raises USD33 Million in Series B Financing 74
Moderna Therapeutics Raises USD450 Million in Venture Financing 76
Definiens Raises USD20.3 Million in Venture Financing Round 78
ZS Pharma Raises USD 55 Million In Series D Financing 79
Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81
G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83
Inotek Pharma Raises USD 21 Million In Venture Financing 84
AesRx Raises USD 1.35 Million In Venture Financing 86
Acerta Pharma Raises Funds through Series A Venture Financing 87
Omthera Pharma Raises USD 17.6 Million In Venture Financing 88
Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89
Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91
Pearl Therapeutics Raises USD 65 Million In Series D Financing 92
Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94
ZS Pharma Raises USD 46 Million In Series C Financing 96
Definiens Raises USD 13 Million In Venture Financing 98
Coferon Raises USD 12 Million In Series B Venture Financing Round 99
ZS Pharma Secures Additional USD 1 Million In Series A Financing 100
ADC Therapeutics To Raise USD 50 Million In Venture Financing 101
Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103
Private Equity 104
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104
Partnerships 106
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106
Biothera Pharma Enters into Partnership with AstraZeneca 107
Voluntis Enters into Collaboration Agreement with AstraZeneca 108
Immunomedics Enters into Partnership with AstraZeneca 109
MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110
Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111
Molecular Partners and AstraZeneca Enter into Partnership 112
Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113
Bavarian Nordic Enters into Partnership with Astrazeneca 114
Syndax Pharma Enters into Agreement with AstraZeneca 115
Innate Pharma Expands Agreement with MedImmune 116
X-Chem Enters into Agreement with AstraZeneca 117
AstraZeneca and Imperial College London Enter into Research Partnership 118
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119
AstraZeneca Forms Joint Venture with SDIC Fund 120
AstraZeneca Enters into Agreement with University of Michigan 121
AstraZeneca and MedImmune Expands Agreement with Incyte 122
Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123
Roivant Sciences Enters into Development Partnership with AstraZeneca 124
NewLink Genetics Enters into Agreement with AstraZeneca 125
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126
BERG Enters into Research Partnership with AstraZeneca 127
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128
Champions Oncology Enters into Agreement with AstraZeneca 129
AstraZeneca Enters into Agreement with Merck 130
MedImmune Enters into Agreement with Washington University School of Medicine 131
Pieris Pharma Enters into Development Agreement with AstraZeneca 132
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133
Genomic Vision Enters into Partnership with AstraZeneca 134
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135
Sanofi Enters into Co-Development Agreement with MedImmune 136
APT Therapeutics Enters into Agreement with AstraZeneca 137
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138
Bicycle Therapeutics Expands into Agreement with AstraZeneca 139
MedImmune Enters into Co-Development Agreement with Abpro 140
AstraZeneca Enters into Co-Marketing Agreement with Aspen 141
Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142
Centre for Drug Research and Development Partners with AstraZeneca 143
Foundation Medicine Enters into Agreement with AstraZeneca 144
MedImmune Enters into Agreement with Genisphere 145
Esteve Enters into Agreement with AstraZeneca 146
Foundation Medicine Partners with AstraZeneca 147
Daewoong Pharma Enters into Agreement with AstraZeneca 148
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149
Lipigon Pharma Enters into Research Agreement with AstraZeneca 150
PROOF Centre Partners with AstraZeneca 151
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152
Allergan Enters into Co-Development Agreement with AstraZeneca 153
Cepheid, MedImmune and Combacte Enter into Agreement 154
Incyte Enters into Agreement with AstraZeneca 155
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156
Rani Therapeutics Enters into Agreement with MedImmune 157
AstraZeneca Enters into Agreement with WuXi AppTec 158
AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162
Hutchison MediPharma Enters into Agreement with AstraZeneca 163
Alvogen Enters into Marketing Agreement with AstraZeneca 164
AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165
Peregrine Pharma Expands its Agreement with AstraZeneca 166
Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167
MedImmune Enters into Research Agreement with University of Sheffield 168
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169
AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170
AstraZeneca Enters into Research Agreement with Inserm 171
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172
AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174
AstraZeneca Expands Research Agreement with Eli Lilly 175
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177
AstraZeneca Enters into Research Agreement with Sutter Health 178
Celgene Enters into Co-Development Agreement with MedImmune 179
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180
MedImmune Enters into Agreement with Juno Therapeutics 181
Bina Technologies Enters into Agreement with AstraZeneca 182
AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183
PatientsLikeMe Enters into Research Agreement with AstraZeneca 184
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186
MedImmune Enters into Research Agreement with Joslin Diabetes Center 187
Orca Pharma Enters into Development Agreement with AstraZeneca 188
MedImmune Enters into Research Agreement with University of Manchester 189
MedImmune Enters into Research Agreement with COEBP 190
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192
AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193
AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194
Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196
MedImmune Enters into Co-Development Agreement with National Cancer Institute 197
Molplex Enters into Research Collaboration with AstraZeneca 198
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199
AstraZeneca Partners with Biognosys 200
Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201
AstraZeneca Forms Joint Venture with University of Manchester 202
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203
Cancer Research UK Forms Joint Venture with MedImmune 205
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206
Astrazeneca Enters into Research Agreement with Redx Pharma 207
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208
AstraZeneca Enters into Co-Development Agreement with Qiagen 209
AstraZeneca Enters into Co-Development Agreement with Roche 210
Advaxis Enters into Agreement with MedImmune 211
AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212
AstraZeneca Extends Collaboration with MRC Technology 213
AstraZeneca Extends its Co-Development Agreement with MRC 214
AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215
Gustave Roussy Enters into Research Agreement with AstraZeneca 216
AstraZeneca Forms Joint Venture with Samsung Biologics 217
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218
AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220
MedImmune Enters Research Agreement With University of Texas MD Anderson 221
MedImmune Enters Into Research Agreement With Cambridge University 222
Biolojic Design Enters into Partnership with MedImmune 223
AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224
MedImmune Enters Into Research Agreement With Johns Hopkins University 225
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227
AstraZeneca Enters Into Research Agreement With Lieber Institute 228
A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229
Taris BioMedical Enters Into Research Agreement With AstraZeneca 231
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233
X-Chem Extends Drug Discovery Agreement With AstraZeneca 234
Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235
AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237
Biosortia Pharma Enters into Research Agreement with AstraZeneca 238
Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243
NeoMed Enters Into Research Agreement With AstraZeneca 245
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247
AstraZeneca Plc - Key Competitors 470
AstraZeneca Plc - Key Employees 471
AstraZeneca Plc - Locations And Subsidiaries 474
Head Office 474
Other Locations & Subsidiaries 474
Joint Venture 480
Recent Developments 481
Strategy And Business Planning 481
Jan 17, 2018: CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub 481
Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZeneca’s BioVentureHub 482
Apr 25, 2017: AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK 483
Financial Announcements 485
Jul 26, 2018: AstraZeneca announces H1 2018 results 485
May 18, 2018: AstraZeneca: Q1 2018 Results 499
Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 501
Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 503
Jul 27, 2017: AstraZeneca Announce H1 2017 Results 511
Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 521
Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 522
Corporate Communications 523
Sep 06, 2018: AstraZeneca: Directorate change 523
Jun 26, 2018: AstraZeneca Announces Board Committee Changes 524
Apr 05, 2018: AstraZeneca: Non-Executive Directors' Retirement Plans 525
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 526
Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 527
Aug 16, 2017: Astrazeneca Non-executive Director Retirement 529
Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 530
Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 531
May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 532
Mar 06, 2017: Changes to AstraZeneca Board of Directors 533
Jan 27, 2017: AstraZeneca announces availability of saxa / dapa FDC in UK 534
Legal and Regulatory 535
Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 535
Aug 07, 2018: AG Paxton recovers $110 million for Texas in medicaid fraud settlements 536
Aug 01, 2018: AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists 537
Jul 26, 2018: US Department of Justice probes Astrazeneca over alleged funding to Iraqi terrorists 538
Government and Public Interest 539
Jul 19, 2018: AstraZeneca to stockpile medicines in preparation for no-deal Brexit 539
Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 540
Jan 24, 2018: A New Ecosystem Approach to Fight Antibiotic Resistance 541
Jan 11, 2018: New research improves our understanding of cancer cell regulation 543
List Of Figure
List of Figures
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25
List Of Table
List of Tables
AstraZeneca Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
AstraZeneca Plc, Deals By Therapy Area, 2012 to YTD 2018 23
AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53
MedImmune Acquires Patent Rights and Technologies from Allozyne 55
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60
AstraZeneca Acquires Neuroscience Assets From Link Medicine 62
PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63
Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65
Albireo to Raise USD10 Million in Venture Financing 67
G1 Therapeutics Raises USD47 Million in Series C Financing 68
Rani Therapeutics Raises Funds in Financing 70
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72
G1 Therapeutics Raises USD33 Million in Series B Financing 74
Moderna Therapeutics Raises USD450 Million in Venture Financing 76
Definiens Raises USD20.3 Million in Venture Financing Round 78
ZS Pharma Raises USD 55 Million In Series D Financing 79
Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81
G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83
Inotek Pharma Raises USD 21 Million In Venture Financing 84
AesRx Raises USD 1.35 Million In Venture Financing 86
Acerta Pharma Raises Funds through Series A Venture Financing 87
Omthera Pharma Raises USD 17.6 Million In Venture Financing 88
Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89
Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91
Pearl Therapeutics Raises USD 65 Million In Series D Financing 92
Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94
ZS Pharma Raises USD 46 Million In Series C Financing 96
Definiens Raises USD 13 Million In Venture Financing 98
Coferon Raises USD 12 Million In Series B Venture Financing Round 99
ZS Pharma Secures Additional USD 1 Million In Series A Financing 100
ADC Therapeutics To Raise USD 50 Million In Venture Financing 101
Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106
Biothera Pharma Enters into Partnership with AstraZeneca 107
Voluntis Enters into Collaboration Agreement with AstraZeneca 108
Immunomedics Enters into Partnership with AstraZeneca 109
MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110
Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111
Molecular Partners and AstraZeneca Enter into Partnership 112
Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113
Bavarian Nordic Enters into Partnership with Astrazeneca 114
Syndax Pharma Enters into Agreement with AstraZeneca 115
Innate Pharma Expands Agreement with MedImmune 116
X-Chem Enters into Agreement with AstraZeneca 117
AstraZeneca and Imperial College London Enter into Research Partnership 118
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119
AstraZeneca Forms Joint Venture with SDIC Fund 120
AstraZeneca Enters into Agreement with University of Michigan 121
AstraZeneca and MedImmune Expands Agreement with Incyte 122
Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123
Roivant Sciences Enters into Development Partnership with AstraZeneca 124
NewLink Genetics Enters into Agreement with AstraZeneca 125
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126
BERG Enters into Research Partnership with AstraZeneca 127
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128
Champions Oncology Enters into Agreement with AstraZeneca 129
AstraZeneca Enters into Agreement with Merck 130
MedImmune Enters into Agreement with Washington University School of Medicine 131
Pieris Pharma Enters into Development Agreement with AstraZeneca 132
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133
Genomic Vision Enters into Partnership with AstraZeneca 134
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135
Sanofi Enters into Co-Development Agreement with MedImmune 136
APT Therapeutics Enters into Agreement with AstraZeneca 137
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138
Bicycle Therapeutics Expands into Agreement with AstraZeneca 139
MedImmune Enters into Co-Development Agreement with Abpro 140
AstraZeneca Enters into Co-Marketing Agreement with Aspen 141
Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142
Centre for Drug Research and Development Partners with AstraZeneca 143
Foundation Medicine Enters into Agreement with AstraZeneca 144
MedImmune Enters into Agreement with Genisphere 145
Esteve Enters into Agreement with AstraZeneca 146
Foundation Medicine Partners with AstraZeneca 147
Daewoong Pharma Enters into Agreement with AstraZeneca 148
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149
Lipigon Pharma Enters into Research Agreement with AstraZeneca 150
PROOF Centre Partners with AstraZeneca 151
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152
Allergan Enters into Co-Development Agreement with AstraZeneca 153
Cepheid, MedImmune and Combacte Enter into Agreement 154
Incyte Enters into Agreement with AstraZeneca 155
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156
Rani Therapeutics Enters into Agreement with MedImmune 157
AstraZeneca Enters into Agreement with WuXi AppTec 158
AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162
Hutchison MediPharma Enters into Agreement with AstraZeneca 163
Alvogen Enters into Marketing Agreement with AstraZeneca 164
AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165
Peregrine Pharma Expands its Agreement with AstraZeneca 166
Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167
MedImmune Enters into Research Agreement with University of Sheffield 168
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169
AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170
AstraZeneca Enters into Research Agreement with Inserm 171
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172
AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174
AstraZeneca Expands Research Agreement with Eli Lilly 175
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177
AstraZeneca Enters into Research Agreement with Sutter Health 178
Celgene Enters into Co-Development Agreement with MedImmune 179
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180
MedImmune Enters into Agreement with Juno Therapeutics 181
Bina Technologies Enters into Agreement with AstraZeneca 182
AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183
PatientsLikeMe Enters into Research Agreement with AstraZeneca 184
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186
MedImmune Enters into Research Agreement with Joslin Diabetes Center 187
Orca Pharma Enters into Development Agreement with AstraZeneca 188
MedImmune Enters into Research Agreement with University of Manchester 189
MedImmune Enters into Research Agreement with COEBP 190
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192
AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193
AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194
Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196
MedImmune Enters into Co-Development Agreement with National Cancer Institute 197
Molplex Enters into Research Collaboration with AstraZeneca 198
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199
AstraZeneca Partners with Biognosys 200
Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201
AstraZeneca Forms Joint Venture with University of Manchester 202
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203
Cancer Research UK Forms Joint Venture with MedImmune 205
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206
Astrazeneca Enters into Research Agreement with Redx Pharma 207
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208
AstraZeneca Enters into Co-Development Agreement with Qiagen 209
AstraZeneca Enters into Co-Development Agreement with Roche 210
Advaxis Enters into Agreement with MedImmune 211
AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212
AstraZeneca Extends Collaboration with MRC Technology 213
AstraZeneca Extends its Co-Development Agreement with MRC 214
AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215
Gustave Roussy Enters into Research Agreement with AstraZeneca 216
AstraZeneca Forms Joint Venture with Samsung Biologics 217
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218
AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220
MedImmune Enters Research Agreement With University of Texas MD Anderson 221
MedImmune Enters Into Research Agreement With Cambridge University 222
Biolojic Design Enters into Partnership with MedImmune 223
AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224
MedImmune Enters Into Research Agreement With Johns Hopkins University 225
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227
AstraZeneca Enters Into Research Agreement With Lieber Institute 228
A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229
Taris BioMedical Enters Into Research Agreement With AstraZeneca 231
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233
X-Chem Extends Drug Discovery Agreement With AstraZeneca 234
Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235
AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237
Biosortia Pharma Enters into Research Agreement with AstraZeneca 238
Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243
NeoMed Enters Into Research Agreement With AstraZeneca 245
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 248
AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 249
AstraZeneca Enters Into Co-Development Agreement With Petrov Institute 250
AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 251
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 252
Serina Therapeutics Enters into Co-Development Agreement with AstraZeneca 253
Cellular Dynamics International Enters Into Agreement With AstraZeneca On Use Of iPSC-Derived Human Cells In Drug Discovery 254
CytImmune Sciences and AstraZeneca Enter into Research Agreement 255
AstraZeneca Enters into Agreement with LegoChem for Antibiotic-Resistant Bacterial Infections 256
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 257
AstraZeneca Expands Co-Development Agreement with Isis Pharma 258
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 259
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 260
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 261
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 262
Charles River Labs Expands its Agreement with AstraZeneca 264
Pharmaron Enters Into Drug Discovery Agreement With AstraZeneca 265
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 266
AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 268
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 269
Starpharma Holdings Enters into Agreement with AstraZeneca 270
Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 271
Knode Enters Into Co-Development Agreement With AstraZeneca 273
Assay Depot Enters Into Joint Venture Agreement With AstraZeneca 274
AstraZeneca Enters Into Co-Development Agreement With Cellworks Group 275
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 276
X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 277
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 278
AstraZeneca And Conformetrix Enter Into Co-Development Agreement 279
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 280
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 281
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 283
AstraZeneca Rumored To Merge With Amgen 284
Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 285
AstraZeneca Enters into Licensing Agreement with Ionis Pharma 286
MedImmune Enters into Licensing Agreement with Compugen 287
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 288
Kiniksa Pharma Enters into Licensing Agreement with MedImmune 289
AstraZeneca Plc, Key Competitors 470
AstraZeneca Plc, Key Employees 471
AstraZeneca Plc, Subsidiaries 474
AstraZeneca Plc, Joint Venture 480
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
AstraZeneca Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. It is also developing new approaches to the treatment of asthma. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
AstraZeneca Plc (AZN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 13
List of Figures 19
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deal Details 48
Asset Purchase 48
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53
MedImmune Acquires Patent Rights and Technologies from Allozyne 55
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60
AstraZeneca Acquires Neuroscience Assets From Link Medicine 62
Venture Financing 63
PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63
Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65
Albireo to Raise USD10 Million in Venture Financing 67
G1 Therapeutics Raises USD47 Million in Series C Financing 68
Rani Therapeutics Raises Funds in Financing 70
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72
G1 Therapeutics Raises USD33 Million in Series B Financing 74
Moderna Therapeutics Raises USD450 Million in Venture Financing 76
Definiens Raises USD20.3 Million in Venture Financing Round 78
ZS Pharma Raises USD 55 Million In Series D Financing 79
Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81
G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83
Inotek Pharma Raises USD 21 Million In Venture Financing 84
AesRx Raises USD 1.35 Million In Venture Financing 86
Acerta Pharma Raises Funds through Series A Venture Financing 87
Omthera Pharma Raises USD 17.6 Million In Venture Financing 88
Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89
Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91
Pearl Therapeutics Raises USD 65 Million In Series D Financing 92
Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94
ZS Pharma Raises USD 46 Million In Series C Financing 96
Definiens Raises USD 13 Million In Venture Financing 98
Coferon Raises USD 12 Million In Series B Venture Financing Round 99
ZS Pharma Secures Additional USD 1 Million In Series A Financing 100
ADC Therapeutics To Raise USD 50 Million In Venture Financing 101
Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103
Private Equity 104
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104
Partnerships 106
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106
Biothera Pharma Enters into Partnership with AstraZeneca 107
Voluntis Enters into Collaboration Agreement with AstraZeneca 108
Immunomedics Enters into Partnership with AstraZeneca 109
MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110
Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111
Molecular Partners and AstraZeneca Enter into Partnership 112
Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113
Bavarian Nordic Enters into Partnership with Astrazeneca 114
Syndax Pharma Enters into Agreement with AstraZeneca 115
Innate Pharma Expands Agreement with MedImmune 116
X-Chem Enters into Agreement with AstraZeneca 117
AstraZeneca and Imperial College London Enter into Research Partnership 118
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119
AstraZeneca Forms Joint Venture with SDIC Fund 120
AstraZeneca Enters into Agreement with University of Michigan 121
AstraZeneca and MedImmune Expands Agreement with Incyte 122
Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123
Roivant Sciences Enters into Development Partnership with AstraZeneca 124
NewLink Genetics Enters into Agreement with AstraZeneca 125
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126
BERG Enters into Research Partnership with AstraZeneca 127
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128
Champions Oncology Enters into Agreement with AstraZeneca 129
AstraZeneca Enters into Agreement with Merck 130
MedImmune Enters into Agreement with Washington University School of Medicine 131
Pieris Pharma Enters into Development Agreement with AstraZeneca 132
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133
Genomic Vision Enters into Partnership with AstraZeneca 134
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135
Sanofi Enters into Co-Development Agreement with MedImmune 136
APT Therapeutics Enters into Agreement with AstraZeneca 137
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138
Bicycle Therapeutics Expands into Agreement with AstraZeneca 139
MedImmune Enters into Co-Development Agreement with Abpro 140
AstraZeneca Enters into Co-Marketing Agreement with Aspen 141
Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142
Centre for Drug Research and Development Partners with AstraZeneca 143
Foundation Medicine Enters into Agreement with AstraZeneca 144
MedImmune Enters into Agreement with Genisphere 145
Esteve Enters into Agreement with AstraZeneca 146
Foundation Medicine Partners with AstraZeneca 147
Daewoong Pharma Enters into Agreement with AstraZeneca 148
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149
Lipigon Pharma Enters into Research Agreement with AstraZeneca 150
PROOF Centre Partners with AstraZeneca 151
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152
Allergan Enters into Co-Development Agreement with AstraZeneca 153
Cepheid, MedImmune and Combacte Enter into Agreement 154
Incyte Enters into Agreement with AstraZeneca 155
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156
Rani Therapeutics Enters into Agreement with MedImmune 157
AstraZeneca Enters into Agreement with WuXi AppTec 158
AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162
Hutchison MediPharma Enters into Agreement with AstraZeneca 163
Alvogen Enters into Marketing Agreement with AstraZeneca 164
AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165
Peregrine Pharma Expands its Agreement with AstraZeneca 166
Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167
MedImmune Enters into Research Agreement with University of Sheffield 168
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169
AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170
AstraZeneca Enters into Research Agreement with Inserm 171
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172
AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174
AstraZeneca Expands Research Agreement with Eli Lilly 175
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177
AstraZeneca Enters into Research Agreement with Sutter Health 178
Celgene Enters into Co-Development Agreement with MedImmune 179
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180
MedImmune Enters into Agreement with Juno Therapeutics 181
Bina Technologies Enters into Agreement with AstraZeneca 182
AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183
PatientsLikeMe Enters into Research Agreement with AstraZeneca 184
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186
MedImmune Enters into Research Agreement with Joslin Diabetes Center 187
Orca Pharma Enters into Development Agreement with AstraZeneca 188
MedImmune Enters into Research Agreement with University of Manchester 189
MedImmune Enters into Research Agreement with COEBP 190
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192
AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193
AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194
Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196
MedImmune Enters into Co-Development Agreement with National Cancer Institute 197
Molplex Enters into Research Collaboration with AstraZeneca 198
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199
AstraZeneca Partners with Biognosys 200
Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201
AstraZeneca Forms Joint Venture with University of Manchester 202
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203
Cancer Research UK Forms Joint Venture with MedImmune 205
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206
Astrazeneca Enters into Research Agreement with Redx Pharma 207
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208
AstraZeneca Enters into Co-Development Agreement with Qiagen 209
AstraZeneca Enters into Co-Development Agreement with Roche 210
Advaxis Enters into Agreement with MedImmune 211
AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212
AstraZeneca Extends Collaboration with MRC Technology 213
AstraZeneca Extends its Co-Development Agreement with MRC 214
AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215
Gustave Roussy Enters into Research Agreement with AstraZeneca 216
AstraZeneca Forms Joint Venture with Samsung Biologics 217
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218
AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220
MedImmune Enters Research Agreement With University of Texas MD Anderson 221
MedImmune Enters Into Research Agreement With Cambridge University 222
Biolojic Design Enters into Partnership with MedImmune 223
AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224
MedImmune Enters Into Research Agreement With Johns Hopkins University 225
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227
AstraZeneca Enters Into Research Agreement With Lieber Institute 228
A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229
Taris BioMedical Enters Into Research Agreement With AstraZeneca 231
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233
X-Chem Extends Drug Discovery Agreement With AstraZeneca 234
Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235
AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237
Biosortia Pharma Enters into Research Agreement with AstraZeneca 238
Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243
NeoMed Enters Into Research Agreement With AstraZeneca 245
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247
AstraZeneca Plc - Key Competitors 470
AstraZeneca Plc - Key Employees 471
AstraZeneca Plc - Locations And Subsidiaries 474
Head Office 474
Other Locations & Subsidiaries 474
Joint Venture 480
Recent Developments 481
Strategy And Business Planning 481
Jan 17, 2018: CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub 481
Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZeneca’s BioVentureHub 482
Apr 25, 2017: AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK 483
Financial Announcements 485
Jul 26, 2018: AstraZeneca announces H1 2018 results 485
May 18, 2018: AstraZeneca: Q1 2018 Results 499
Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 501
Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 503
Jul 27, 2017: AstraZeneca Announce H1 2017 Results 511
Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 521
Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 522
Corporate Communications 523
Sep 06, 2018: AstraZeneca: Directorate change 523
Jun 26, 2018: AstraZeneca Announces Board Committee Changes 524
Apr 05, 2018: AstraZeneca: Non-Executive Directors' Retirement Plans 525
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 526
Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 527
Aug 16, 2017: Astrazeneca Non-executive Director Retirement 529
Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 530
Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 531
May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 532
Mar 06, 2017: Changes to AstraZeneca Board of Directors 533
Jan 27, 2017: AstraZeneca announces availability of saxa / dapa FDC in UK 534
Legal and Regulatory 535
Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 535
Aug 07, 2018: AG Paxton recovers $110 million for Texas in medicaid fraud settlements 536
Aug 01, 2018: AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists 537
Jul 26, 2018: US Department of Justice probes Astrazeneca over alleged funding to Iraqi terrorists 538
Government and Public Interest 539
Jul 19, 2018: AstraZeneca to stockpile medicines in preparation for no-deal Brexit 539
Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 540
Jan 24, 2018: A New Ecosystem Approach to Fight Antibiotic Resistance 541
Jan 11, 2018: New research improves our understanding of cancer cell regulation 543
List Of Figure
List of Figures
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25
List Of Table
List of Tables
AstraZeneca Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
AstraZeneca Plc, Deals By Therapy Area, 2012 to YTD 2018 23
AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53
MedImmune Acquires Patent Rights and Technologies from Allozyne 55
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60
AstraZeneca Acquires Neuroscience Assets From Link Medicine 62
PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63
Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65
Albireo to Raise USD10 Million in Venture Financing 67
G1 Therapeutics Raises USD47 Million in Series C Financing 68
Rani Therapeutics Raises Funds in Financing 70
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72
G1 Therapeutics Raises USD33 Million in Series B Financing 74
Moderna Therapeutics Raises USD450 Million in Venture Financing 76
Definiens Raises USD20.3 Million in Venture Financing Round 78
ZS Pharma Raises USD 55 Million In Series D Financing 79
Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81
G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83
Inotek Pharma Raises USD 21 Million In Venture Financing 84
AesRx Raises USD 1.35 Million In Venture Financing 86
Acerta Pharma Raises Funds through Series A Venture Financing 87
Omthera Pharma Raises USD 17.6 Million In Venture Financing 88
Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89
Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91
Pearl Therapeutics Raises USD 65 Million In Series D Financing 92
Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94
ZS Pharma Raises USD 46 Million In Series C Financing 96
Definiens Raises USD 13 Million In Venture Financing 98
Coferon Raises USD 12 Million In Series B Venture Financing Round 99
ZS Pharma Secures Additional USD 1 Million In Series A Financing 100
ADC Therapeutics To Raise USD 50 Million In Venture Financing 101
Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106
Biothera Pharma Enters into Partnership with AstraZeneca 107
Voluntis Enters into Collaboration Agreement with AstraZeneca 108
Immunomedics Enters into Partnership with AstraZeneca 109
MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110
Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111
Molecular Partners and AstraZeneca Enter into Partnership 112
Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113
Bavarian Nordic Enters into Partnership with Astrazeneca 114
Syndax Pharma Enters into Agreement with AstraZeneca 115
Innate Pharma Expands Agreement with MedImmune 116
X-Chem Enters into Agreement with AstraZeneca 117
AstraZeneca and Imperial College London Enter into Research Partnership 118
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119
AstraZeneca Forms Joint Venture with SDIC Fund 120
AstraZeneca Enters into Agreement with University of Michigan 121
AstraZeneca and MedImmune Expands Agreement with Incyte 122
Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123
Roivant Sciences Enters into Development Partnership with AstraZeneca 124
NewLink Genetics Enters into Agreement with AstraZeneca 125
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126
BERG Enters into Research Partnership with AstraZeneca 127
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128
Champions Oncology Enters into Agreement with AstraZeneca 129
AstraZeneca Enters into Agreement with Merck 130
MedImmune Enters into Agreement with Washington University School of Medicine 131
Pieris Pharma Enters into Development Agreement with AstraZeneca 132
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133
Genomic Vision Enters into Partnership with AstraZeneca 134
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135
Sanofi Enters into Co-Development Agreement with MedImmune 136
APT Therapeutics Enters into Agreement with AstraZeneca 137
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138
Bicycle Therapeutics Expands into Agreement with AstraZeneca 139
MedImmune Enters into Co-Development Agreement with Abpro 140
AstraZeneca Enters into Co-Marketing Agreement with Aspen 141
Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142
Centre for Drug Research and Development Partners with AstraZeneca 143
Foundation Medicine Enters into Agreement with AstraZeneca 144
MedImmune Enters into Agreement with Genisphere 145
Esteve Enters into Agreement with AstraZeneca 146
Foundation Medicine Partners with AstraZeneca 147
Daewoong Pharma Enters into Agreement with AstraZeneca 148
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149
Lipigon Pharma Enters into Research Agreement with AstraZeneca 150
PROOF Centre Partners with AstraZeneca 151
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152
Allergan Enters into Co-Development Agreement with AstraZeneca 153
Cepheid, MedImmune and Combacte Enter into Agreement 154
Incyte Enters into Agreement with AstraZeneca 155
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156
Rani Therapeutics Enters into Agreement with MedImmune 157
AstraZeneca Enters into Agreement with WuXi AppTec 158
AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162
Hutchison MediPharma Enters into Agreement with AstraZeneca 163
Alvogen Enters into Marketing Agreement with AstraZeneca 164
AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165
Peregrine Pharma Expands its Agreement with AstraZeneca 166
Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167
MedImmune Enters into Research Agreement with University of Sheffield 168
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169
AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170
AstraZeneca Enters into Research Agreement with Inserm 171
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172
AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174
AstraZeneca Expands Research Agreement with Eli Lilly 175
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177
AstraZeneca Enters into Research Agreement with Sutter Health 178
Celgene Enters into Co-Development Agreement with MedImmune 179
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180
MedImmune Enters into Agreement with Juno Therapeutics 181
Bina Technologies Enters into Agreement with AstraZeneca 182
AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183
PatientsLikeMe Enters into Research Agreement with AstraZeneca 184
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186
MedImmune Enters into Research Agreement with Joslin Diabetes Center 187
Orca Pharma Enters into Development Agreement with AstraZeneca 188
MedImmune Enters into Research Agreement with University of Manchester 189
MedImmune Enters into Research Agreement with COEBP 190
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192
AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193
AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194
Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196
MedImmune Enters into Co-Development Agreement with National Cancer Institute 197
Molplex Enters into Research Collaboration with AstraZeneca 198
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199
AstraZeneca Partners with Biognosys 200
Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201
AstraZeneca Forms Joint Venture with University of Manchester 202
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203
Cancer Research UK Forms Joint Venture with MedImmune 205
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206
Astrazeneca Enters into Research Agreement with Redx Pharma 207
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208
AstraZeneca Enters into Co-Development Agreement with Qiagen 209
AstraZeneca Enters into Co-Development Agreement with Roche 210
Advaxis Enters into Agreement with MedImmune 211
AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212
AstraZeneca Extends Collaboration with MRC Technology 213
AstraZeneca Extends its Co-Development Agreement with MRC 214
AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215
Gustave Roussy Enters into Research Agreement with AstraZeneca 216
AstraZeneca Forms Joint Venture with Samsung Biologics 217
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218
AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220
MedImmune Enters Research Agreement With University of Texas MD Anderson 221
MedImmune Enters Into Research Agreement With Cambridge University 222
Biolojic Design Enters into Partnership with MedImmune 223
AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224
MedImmune Enters Into Research Agreement With Johns Hopkins University 225
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227
AstraZeneca Enters Into Research Agreement With Lieber Institute 228
A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229
Taris BioMedical Enters Into Research Agreement With AstraZeneca 231
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233
X-Chem Extends Drug Discovery Agreement With AstraZeneca 234
Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235
AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237
Biosortia Pharma Enters into Research Agreement with AstraZeneca 238
Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243
NeoMed Enters Into Research Agreement With AstraZeneca 245
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 248
AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 249
AstraZeneca Enters Into Co-Development Agreement With Petrov Institute 250
AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 251
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 252
Serina Therapeutics Enters into Co-Development Agreement with AstraZeneca 253
Cellular Dynamics International Enters Into Agreement With AstraZeneca On Use Of iPSC-Derived Human Cells In Drug Discovery 254
CytImmune Sciences and AstraZeneca Enter into Research Agreement 255
AstraZeneca Enters into Agreement with LegoChem for Antibiotic-Resistant Bacterial Infections 256
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 257
AstraZeneca Expands Co-Development Agreement with Isis Pharma 258
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 259
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 260
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 261
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 262
Charles River Labs Expands its Agreement with AstraZeneca 264
Pharmaron Enters Into Drug Discovery Agreement With AstraZeneca 265
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 266
AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 268
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 269
Starpharma Holdings Enters into Agreement with AstraZeneca 270
Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 271
Knode Enters Into Co-Development Agreement With AstraZeneca 273
Assay Depot Enters Into Joint Venture Agreement With AstraZeneca 274
AstraZeneca Enters Into Co-Development Agreement With Cellworks Group 275
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 276
X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 277
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 278
AstraZeneca And Conformetrix Enter Into Co-Development Agreement 279
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 280
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 281
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 283
AstraZeneca Rumored To Merge With Amgen 284
Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 285
AstraZeneca Enters into Licensing Agreement with Ionis Pharma 286
MedImmune Enters into Licensing Agreement with Compugen 287
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 288
Kiniksa Pharma Enters into Licensing Agreement with MedImmune 289
AstraZeneca Plc, Key Competitors 470
AstraZeneca Plc, Key Employees 471
AstraZeneca Plc, Subsidiaries 474
AstraZeneca Plc, Joint Venture 480
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
AstraZeneca Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020